CD19 and acute lymphoblastic leukemia: Humanize the framework regions of the original llama-derived nanobodies and screen out clones with better anti-tumor abilities than the parental NbD4 nanoCAR. The H24 nanoCARs have been found to effectively target ALL relapses after CD19 CAR-T therapy